Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:ARCB) with a Overweight and raises the price target from $90 to $96.
Uncategorized
Morgan Stanley Maintains Overweight on ArcBest, Raises Price Target to $96
Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:ARCB) with a Overweight and raises the price target from $90 to $96.
Related Posts
Where Sempra Energy Stands With Analysts
Sempra Energy (NYSE:SRE) has observed the following analyst ratings within the last quarter:
Argus Research Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $340
Argus Research analyst Jasper Hellweg maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $320 to $340.
Volta Shares Spike To Session High As Traders Circulate Seeking Alpha Blog Post From Biotechlab Highlighting $30 Price Target In Stock
https://seekingalpha.com/instablog/2694641-biotechlab/5656281-vlta-price-target-30_00